Press Releases Archives - Page 33 of 103 - Lupin

BSE 2442.35 NSE 2442.90

indian flag icon

India

USA

great-britain flag icon

UK

south-africa flag icon

South Africa

australia flag icon

Australia

philippines flag icon

Philippines

germany flag icon

Germany

netherlands flag icon

Netherlands

mexico flag icon

Mexico

brazil flag icon

Brazil

canada flag icon

Canada

Switzerland flag icon

Switzerland

BSE 2442.35 NSE 2442.90

Lupin Enters into Licensing Agreement with Alvion to market Cardiometabolic Drugs in the Southeast Asia region

Lupin Receives Approval from U.S. FDA for Sildenafil for Oral Suspension

Lupin Receives Approval from U.S. FDA for Vigabatrin for Oral Solution USP

Lupin Launches its First Reference Laboratory in East India Establishing its Diagnostics Business in Kolkata

Lupin Teams up with Mary Kom to Raise Awareness Amongst Women on Cardiovascular Disease

Lupin signs on Mary Kom for its Women’s Cardiovascular Health Awareness Initiative, Shakti

Lupin Receives Approval from U.S. FDA for Efinaconazole Topical Solution

Lupin Launches Sevelamer Hydrochloride Tablets in the United States

Lupin Announces Executive Leadership Change, Dr. Fabrice Egros to assume Corporate Development responsibilities as President, Corporate Development & Growth Markets

February 23, 2022

Lupin Announces FDA Approval of Supplemental New Drug Application for SOLOSEC® (secnidazole) in Adolescents for both the Treatment of Bacterial Vaginosis in Females and Trichomoniasis

February 17, 2022

1 2 … 32 33 34 … 102 103

Search

Hit enter to search or ESC to close